Connection
David Simpson to Prognosis
This is a "connection" page, showing publications David Simpson has written about Prognosis.
|
|
Connection Strength |
|
 |
|
 |
|
0.243 |
|
|
|
-
Turner-Stokes L, Ashford S, Esquenazi A, Wissel J, Ward AB, Francisco G, Lains J, Suputtitada A, Serrano S, Baguley IJ, Barnes M, Simpson DM. A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework. Eur J Phys Rehabil Med. 2018 Aug; 54(4):605-617.
Score: 0.086
-
Robinson-Papp J, Simpson DM. Neuromuscular complications of human immunodeficiency virus infection. Phys Med Rehabil Clin N Am. 2008 Feb; 19(1):81-96, vi-vii.
Score: 0.043
-
Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 03; 34(3):787-798.
Score: 0.024
-
Jia P, Zhao Z, Hulgan T, Bush WS, Samuels DC, Bloss CS, Heaton RK, Ellis RJ, Schork N, Marra CM, Collier AC, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, McCutchan JA, Barnholtz-Sloan JS, Franklin DR, Rosario D, Letendre SL, Grant I, Kallianpur AR. Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study. Am J Med Genet B Neuropsychiatr Genet. 2017 Jun; 174(4):413-426.
Score: 0.021
-
Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Ill?s ?, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 03; 18(3):297-311.
Score: 0.020
-
Hammond ER, Crum RM, Treisman GJ, Mehta SH, Clifford DB, Ellis RJ, Gelman BB, Grant I, Letendre SL, Marra CM, Morgello S, Simpson DM, Mcarthur JC. Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neurovirol. 2016 08; 22(4):479-87.
Score: 0.019
-
Grant I, Franklin DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Heaton RK. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 Jun 10; 82(23):2055-62.
Score: 0.017
-
Post MJ, Yiannoutsos C, Simpson D, Booss J, Clifford DB, Cohen B, McArthur JC, Hall CD. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol. 1999 Nov-Dec; 20(10):1896-906.
Score: 0.006
-
Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology. 1999 Feb; 52(3):623-5.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|